New targeted therapy aims at Hard-to-Treat cancers

NCT ID NCT07349537

First seen Jan 17, 2026 · Last updated Apr 29, 2026 · Updated 19 times

Summary

This early-stage study tests an experimental drug called RMC-5127 in adults with advanced solid tumors that have a specific KRAS G12V mutation. The main goals are to check the drug's safety, how the body processes it, and whether it can shrink tumors. About 574 participants will receive the drug alone or combined with other treatments.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • NEXT

    RECRUITING

    San Antonio, Texas, 78229, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • NEXT - Dallas

    RECRUITING

    Dallas, Texas, 75039, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • NEXT - Virginia

    RECRUITING

    Fairfax, Virginia, 22031, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • START - San Antonio

    RECRUITING

    San Antonio, Texas, 78229, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • START Midwest

    RECRUITING

    Grand Rapids, Michigan, 49546, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.